"A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease."

A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease

Registry ID

EUCTR2006-006497-17

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

Merck & Co. Inc

Start date

2007-07-24

Completion date

2008-07-16

Last update

2026-08-16

Conditions

• Hypercholesterolemia
• metabolic syndrome and hypercholesterolemia

Summary

In high risk patients for CHD with metabolic syndrome and hypercholesterolemia, to evaluate the LDL-C lowering efficacy of the ezetimibe/simvastatin combination tablet compared to atorvastatin.

Locations

• , , Germany
• , , Netherlands
• , , Hungary
• , , Italy
• , , Greece

Related clinical trials

• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
• Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
• Causes and Natural History of Dyslipidemias
• A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
• A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
• Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

View on source registry